Study · Non-randomized trial · n = 138 · 2022

6 results

Efficacy of Thymosin α1 in Management of Radiation Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiotherapy: A Phase 2 Clinical Trial (GASTO-1043).

Liu F, Qiu B, Xi Y, Luo Y, Luo Q, Wu Y, Chen N, Zhou R, Guo J, Wu Q, Xiong M, Liu H

International journal of radiation oncology, biology, physics21 Jul 2022Cited by 26 (Europe PMC)

PMID35870709DOI10.1016/j.ijrobp.2022.07.009PepBankPUB-35870709

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy, thymosin alpha‑1 was linked to a lower incidence of grade 2 or higher radiation pneumonitis than in matched controls.
In plain wordsIn people with lung cancer treated with chemoradiotherapy, thymosin alpha‑1 was linked to less radiation lung inflammation than in matched controls.
Peptide
Thymosin alpha-1
Outcome
DecreaseIncidence of grade 2 or higher radiation pneumonitis
Study
n = 138
Comparator
Concurrent chemoradiotherapy without thymosin alpha 1 (propensity-matched controls)
Analysis
Primary
Outcome group
Adverse events · Respiratory
Studied dose
Dose not stated · From the start of chemoradiotherapy until 2 months after itAs given in this study (human).
Measurements
Incidence of G>=2 RP
36.2%
thymosin alpha 1 group
Incidence of G>=2 RP
53.6%
control group
Source sentences
Summary
The incidence of G≥2 RP was lower in the study group compared with control cases (36.2% vs 53.6%, P = .040).
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible patients received definitive CCRT and weekly thymosin α1 from the start of CCRT until 2 months after CCRT.
Summary · context
Patients treated with CCRT but without thymosin α1 intervention during the same period were selected as the control group by the propensity score matching method.
Report a problemFND-3587070901
02HumanNon-randomized trialEfficacy outcome
In patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy, thymosin alpha‑1 was linked to a lower incidence of grade 3 to 4 lymphopenia than in matched controls.
In plain wordsIn people with lung cancer treated with chemoradiotherapy, thymosin alpha‑1 was linked to less severe low lymphocyte counts than in matched controls.
Peptide
Thymosin alpha-1
Outcome
DecreaseIncidence of grade 3 to 4 lymphopenia
Study
n = 138
Comparator
Concurrent chemoradiotherapy without thymosin alpha 1 (propensity-matched controls)
Analysis
Secondary
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · From the start of chemoradiotherapy until 2 months after itAs given in this study (human).
Measurements
Incidence of G3-4 lymphopenia
19.1%
thymosin alpha 1 group
Incidence of G3-4 lymphopenia
62.1%
control group
Source sentences
Summary
Compared with the control group, the incidence of G3 to G4 lymphopenia (19.1% vs 62.1%, P < .001) was lower, and the median TLC nadir (0.51 k/µL vs 0.30 k/µL, P < .001) was higher in the study group.
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible patients received definitive CCRT and weekly thymosin α1 from the start of CCRT until 2 months after CCRT.
Summary · context
Patients treated with CCRT but without thymosin α1 intervention during the same period were selected as the control group by the propensity score matching method.
Report a problemFND-3587070903
03HumanNon-randomized trialEfficacy outcome
In patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy, the median total lymphocyte count nadir was higher with thymosin alpha‑1 than in matched controls.
In plain wordsIn people with lung cancer treated with chemoradiotherapy, the lowest lymphocyte count was higher with thymosin alpha‑1 than in matched controls.
Peptide
Thymosin alpha-1
Outcome
IncreaseMedian total lymphocyte count nadir
Study
n = 138
Comparator
Concurrent chemoradiotherapy without thymosin alpha 1 (propensity-matched controls)
Analysis
Secondary
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · From the start of chemoradiotherapy until 2 months after itAs given in this study (human).
Measurements
Median TLC nadir
0.51 k/µL
thymosin alpha 1 group
Median TLC nadir
0.3 k/µL
control group
Source sentences
Summary
Compared with the control group, the incidence of G3 to G4 lymphopenia (19.1% vs 62.1%, P < .001) was lower, and the median TLC nadir (0.51 k/µL vs 0.30 k/µL, P < .001) was higher in the study group.
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible patients received definitive CCRT and weekly thymosin α1 from the start of CCRT until 2 months after CCRT.
Summary · context
Patients treated with CCRT but without thymosin α1 intervention during the same period were selected as the control group by the propensity score matching method.
Report a problemFND-3587070904
04HumanNon-randomized trialEfficacy outcome
In patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy, gut microbiota diversity and composition did not differ significantly between the thymosin alpha‑1 group and matched controls.
In plain wordsIn people with lung cancer treated with chemoradiotherapy, gut bacteria did not differ significantly between those given thymosin alpha‑1 and matched controls.
Peptide
Thymosin alpha-1
Outcome
No significant changeGut microbiota diversity and composition
Study
n = 138
Comparator
Concurrent chemoradiotherapy without thymosin alpha 1 (propensity-matched controls)
Analysis
Secondary
Outcome group
Immune response · Gastrointestinal
Studied dose
Dose not stated · From the start of chemoradiotherapy until 2 months after itAs given in this study (human).
Source sentences
Summary
The diversity and community composition of the gut microbiota were not significantly different between the 2 groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible patients received definitive CCRT and weekly thymosin α1 from the start of CCRT until 2 months after CCRT.
Summary · context
Patients treated with CCRT but without thymosin α1 intervention during the same period were selected as the control group by the propensity score matching method.
Report a problemFND-3587070906
05HumanNon-randomized trialEfficacy outcome
In patients with locally advanced non-small cell lung cancer, late grade 1 pulmonary fibrosis did not differ significantly between the thymosin alpha‑1 group and matched controls.
In plain wordsIn people with lung cancer treated with chemoradiotherapy, late lung scarring did not differ significantly between those given thymosin alpha‑1 and matched controls.
Peptide
Thymosin alpha-1
Outcome
No significant changeLate pulmonary fibrosis (grade 1)
Study
n: not reported in source
Comparator
Concurrent chemoradiotherapy without thymosin alpha 1 (propensity-matched controls)
Analysis
Secondary
Outcome group
Adverse events · Respiratory
Studied dose
Dose not stated · From the start of chemoradiotherapy until 2 months after itAs given in this study (human).
Source sentences
Summary
G1 late pulmonary fibrosis occurred in 2 (3.7%) patients of the control group compared with no event in the study group (P = .243).
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible patients received definitive CCRT and weekly thymosin α1 from the start of CCRT until 2 months after CCRT.
Summary · context
Patients treated with CCRT but without thymosin α1 intervention during the same period were selected as the control group by the propensity score matching method.
Report a problemFND-3587070902
06HumanNon-randomized trialEfficacy outcome
In patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy, fewer patients had a maximum CRP of at least 100 mg/L with thymosin alpha‑1 than in matched controls.
In plain wordsIn people with lung cancer treated with chemoradiotherapy, fewer had very high CRP, an inflammation marker, with thymosin alpha‑1 than in matched controls.
Peptide
Thymosin alpha-1
Outcome
DecreaseProportion with maximum CRP of 100 mg/L or higher
Study
n: not reported in source
Comparator
Concurrent chemoradiotherapy without thymosin alpha 1 (propensity-matched controls)
Analysis
Secondary
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · From the start of chemoradiotherapy until 2 months after itAs given in this study (human).
Measurements
Proportion with maximum CRP >=100 mg/L
13.8%
thymosin alpha 1 group
Proportion with maximum CRP >=100 mg/L
29.7%
control group
Source sentences
Summary
The proportion of patients with maximum CRP ≥100 mg/L was lower in the study group (13.8% vs 29.7% P = .029).
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible patients received definitive CCRT and weekly thymosin α1 from the start of CCRT until 2 months after CCRT.
Summary · context
Patients treated with CCRT but without thymosin α1 intervention during the same period were selected as the control group by the propensity score matching method.
Report a problemFND-3587070905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 1 completed · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT06178146

Thymosin Alpha-1 for irAE Secondary to ICIs

Jun Wangn = 401 Sept 2023 to est. Apr 2025

IrAE

Trial page ClinicalTrials.govUpdated 20 Dec 2023

CompletedPhase 2NCT06139419

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Sun Yat-sen Universityn = 11425 Jul 2023 to 30 Jun 2026

Non-small Cell Lung Cancer

Trial page ClinicalTrials.govUpdated 3 Aug 2026

Status unknownPhase 2NCT05790447

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Second Affiliated Hospital of Soochow Universityn = 60est. 1 Apr 2023 to est. Dec 2025

Advanced Solid Tumor · Refractory Tumor

Trial page ClinicalTrials.govUpdated 30 Mar 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC